Bionote: IPO Price Reduced Significantly & Bookbuilding Results
Bionote slashed its IPO price to 9,000 won, a 50% lower than the low end of IPO range. Our base case valuation is lowered to 12,741 won per share,...
396 Views
Bionote Pre-IPO Peer Comp - Larger Segment Leads in Margins, but Trend Could Be Reversing
Bionote is looking to raise approximately US$200m in its Korean IPO. The IPO would consist of both a primary and secondary selldown. In this note,...
201 Views
Global Medtech Trends: Readouts from Early Birds of Q3 Earnings Season- Positives and Negatives
Q3 results of large U.S. medtech companies recorded procedure volume growth. However, macroeconomic headwinds are expected to prevail. Similar...
188 Views
Bionote Pre-IPO - The Positives - Expanding Product Portfolio and Vertically Integrated
Bionote (377740 KS) is looking to raise approximately US$200m in its Korean IPO. The IPO would consist of both a primary and secondary selldown.
230 Views
BioNote IPO Valuation Analysis
Our base case valuation is target price of 16,182 won per share, which is 10% lower than the low end of the IPO price range.
240 Views